Pityriasis rosea developing after COVID‐19 vaccination
Orianna Marcantonio, Ainhoa Vidal-Navarro, David Pesqué, Ana M. Giménez‐Arnau, Ramón M. Pujol, Gemma Martín‐Ezquerra
Abstract
A. M. Giménez-Arnau is a medical advisor for Uriach Pharma, Novartis, GSK, Sanofi–Regeneron, Amgen, Thermo Fisher Scientific, Almirall; has received research grants or contracts from Uriach Pharma, Novartis, Instituto Carlos III- FEDER; has Royalties or licences for Springer Contact Urticaria and Syndrome book; and has participated in educational activities sponsored by Novartis, Menarini, LEO-PHARMA, GSK, MSD, Almirall, Sanofi and AVENE. O. Marcantonio-Santa Cruz, A. Vidal-Navarro, D. Pesqué, R.M. Pujol, and G. Martin-Ezquerra declare that they have no conflicts of interest.
Topics & Concepts
MedicineCoronavirus disease 2019 (COVID-19)Family medicineManagementDiseaseInternal medicineInfectious disease (medical specialty)EconomicsDermatological and COVID-19 studiesRabies epidemiology and controlBartonella species infections research